查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1597734

皮下免疫球蛋白市場：按適應症、最終用戶分類 - 全球預測 2025-2030

Subcutaneous Immunoglobulin Market by Indication (Primary Immunodeficiencies, Secondary Immunodeficiencies), End-User (Homecare Settings, Hospitals & Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年皮下免疫球蛋白市場價值為94.7億美元，預計到2024年將達到104.6億美元，複合年成長率為10.82%，到2030年將達到194.6億美元。

皮下免疫球蛋白（SCIg）是指透過皮下注射施用免疫球蛋白的醫學療法，主要用於原發性免疫力缺乏疾病和某些自體免疫疾病的患者。這項需求源自於維持足夠的免疫球蛋白水平的需要，這對於免疫系統受損的患者抵抗感染疾病至關重要。應用範圍從常規家庭輸液（比靜脈注射對患者更方便）到醫院環境（主要針對免疫力缺乏的患者）。最終用途包括醫療保健設施、居家照護場所、專科診所等。免疫不全症盛行率的上升、SCIg 製劑的進步以及患者對家庭治療的偏好的增加對市場成長產生了顯著影響。此外，持續的研究和開發正在創造創新的輸送機制，例如無針系統，這些機制正在引起市場關注。然而，潛在的副作用、高治療成本和監管挑戰等限制因素可能會阻礙市場成長。此外，不同地區患者對治療方案的認知並不一致，增加了挑戰。最近的潛在商機包括將 SCIg 的應用擴展到新的治療領域以及加強開拓市場的銷售網路。抓住這些機會的建議包括投資教育和意識計劃、與醫療保健提供者合作以及遊說有利的報銷政策。改進的輸送裝置和更穩定的免疫球蛋白配方等創新是有希望促進業務成長的研究領域。此外，用於病患監測和管理的數位平台可以提供策略優勢。 SCIg 市場的特點是競爭格局激烈，多個主要企業不斷投資於技術進步。需要策略敏捷性來駕馭監管、患者倡導和競爭格局，同時專注於技術和治療創新以實現持續成長。

主要市場統計
基準年[2023] 94.7億美元
預測年份 [2024] 104.6億美元
預測年份 [2030] 194.6億美元
複合年成長率（%） 10.82%

市場動態：快速發展的皮下免疫球蛋白市場的關鍵市場洞察

供需的動態交互作用正在改變皮下免疫球蛋白市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球自體免疫疾病盛行率上升
    • 仿單標示外使用中皮下免疫球蛋白的使用增加
    • 生技和製藥公司增加對研發項目的投資
  • 市場限制因素
    • 皮下免疫球蛋白治療相關的巨額費用
  • 市場機會
    • 增加政府資助和對皮下免疫球蛋白治療的認知
    • 皮下免疫球蛋白給藥的創新
  • 市場挑戰
    • 嚴格的政府法規和治療副作用的高風險

波特的五力：駕馭皮下免疫球蛋白市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解皮下免疫球蛋白市場的外部影響

外部宏觀環境因素在塑造皮下免疫球蛋白市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解皮下免疫球蛋白市場的競爭格局

皮下免疫球蛋白市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣皮下免疫球蛋白市場供應商的績效評估

FPNV 定位矩陣是評估皮下免疫球蛋白市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃皮下免疫球蛋白市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，皮下免疫球蛋白市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球自體免疫疾病的盛行率上升
      • 在仿單標示外適應症中增加皮下免疫球蛋白的使用
      • 生技和製藥公司增加對研發項目的投資
    • 抑制因素
      • 皮下免疫球蛋白治療的龐大費用
    • 機會
      • 增加政府資助並提高對使用皮下免疫球蛋白治療的認知
      • 皮下免疫球蛋白管理的創新
    • 任務
      • 嚴格的政府法規和治療副作用的高風險
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章皮下免疫球蛋白市場依適應症分類

  • 原發性免疫力缺乏
  • 繼發性免疫力缺乏缺陷

第7章皮下免疫球蛋白市場：依最終用戶分類

  • 家庭護理設置
  • 醫院/診所

第8章北美和南美皮下免疫球蛋白市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太皮下免疫球蛋白市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲皮下免疫球蛋白市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Biotest AG by Grifols SA
  • CSL Behring
  • Kedrion Biopharma Inc.
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
  • The Bio Products Laboratory
Product Code: MRR-FF012EDC38B2

The Subcutaneous Immunoglobulin Market was valued at USD 9.47 billion in 2023, expected to reach USD 10.46 billion in 2024, and is projected to grow at a CAGR of 10.82%, to USD 19.46 billion by 2030.

Subcutaneous immunoglobulin (SCIg) refers to a medical therapy involving the administration of immunoglobulins via subcutaneous injection, primarily deployed in patients with primary immunodeficiency diseases and certain autoimmune disorders. Its necessity arises from the need to maintain adequate immunoglobulin levels, which are vital to fighting infections in patients with compromised immune systems. The application scope extends from regular home-based infusions, thereby offering patients greater convenience compared to intravenous routes, to hospital settings, primarily serving immunocompromised individuals. End-use segments include healthcare facilities, homecare settings, and specialty clinics. Market growth is significantly influenced by the rising prevalence of immunodeficiency disorders, advancements in SCIg formulations, and increasing patient preference for home-based treatments. Additionally, ongoing research and development yield innovative delivery mechanisms, such as needleless systems, which capture market attention. However, the market faces limitations from potential side effects, high costs of treatment, and regulatory challenges, which could hinder growth. Moreover, patient awareness regarding treatment options remains inconsistent across regions, adding to the challenges. The latest potential opportunities include expanding SCIg applications into new therapeutic areas and enhancing distribution networks to untapped markets. Recommendations to capture these opportunities include investment in education and awareness programs, partnerships with healthcare providers, and lobbying for favorable reimbursement policies. Innovations such as improving delivery devices and formulating more stable immunoglobulin preparations are promising areas of research for business growth. Furthermore, digital platforms for patient monitoring and management could present a strategic advantage. The SCIg market is characterized by a competitive landscape with several key players constantly investing in technological advancements. It requires strategic agility to navigate regulatory landscapes, patient advocacy, and competitive pressures while focusing on technological and therapeutic innovations for sustained growth.

KEY MARKET STATISTICS
Base Year [2023] USD 9.47 billion
Estimated Year [2024] USD 10.46 billion
Forecast Year [2030] USD 19.46 billion
CAGR (%) 10.82%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Subcutaneous Immunoglobulin Market

The Subcutaneous Immunoglobulin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the prevalence of autoimmune disorders globally
    • Increasing usage of subcutaneous immunoglobulin in off-label indications
    • Growing investments in R&D programs by biotechnology and pharmaceutical companies
  • Market Restraints
    • Huge cost associated with subcutaneous immunoglobulin treatment
  • Market Opportunities
    • Rising government funding and increasing awareness about the usage of subcutaneous immunoglobulin treatment
    • Innovations in the administration of subcutaneous immunoglobulin
  • Market Challenges
    • Stringent government regulations and high risk of the side effects of the treatment

Porter's Five Forces: A Strategic Tool for Navigating the Subcutaneous Immunoglobulin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Subcutaneous Immunoglobulin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Subcutaneous Immunoglobulin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Subcutaneous Immunoglobulin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Subcutaneous Immunoglobulin Market

A detailed market share analysis in the Subcutaneous Immunoglobulin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Subcutaneous Immunoglobulin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Subcutaneous Immunoglobulin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Subcutaneous Immunoglobulin Market

A strategic analysis of the Subcutaneous Immunoglobulin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Subcutaneous Immunoglobulin Market, highlighting leading vendors and their innovative profiles. These include Biotest AG by Grifols S.A., CSL Behring, Kedrion Biopharma Inc., Octapharma AG, Takeda Pharmaceutical Company Limited, and The Bio Products Laboratory.

Market Segmentation & Coverage

This research report categorizes the Subcutaneous Immunoglobulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Primary Immunodeficiencies and Secondary Immunodeficiencies.
  • Based on End-User, market is studied across Homecare Settings and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence of autoimmune disorders globally
      • 5.1.1.2. Increasing usage of subcutaneous immunoglobulin in off-label indications
      • 5.1.1.3. Growing investments in R&D programs by biotechnology and pharmaceutical companies
    • 5.1.2. Restraints
      • 5.1.2.1. Huge cost associated with subcutaneous immunoglobulin treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising government funding and increasing awareness about the usage of subcutaneous immunoglobulin treatment
      • 5.1.3.2. Innovations in the administration of subcutaneous immunoglobulin
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and high risk of the side effects of the treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Subcutaneous Immunoglobulin Market, by Indication

  • 6.1. Introduction
  • 6.2. Primary Immunodeficiencies
  • 6.3. Secondary Immunodeficiencies

7. Subcutaneous Immunoglobulin Market, by End-User

  • 7.1. Introduction
  • 7.2. Homecare Settings
  • 7.3. Hospitals & Clinics

8. Americas Subcutaneous Immunoglobulin Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Subcutaneous Immunoglobulin Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Subcutaneous Immunoglobulin Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Biotest AG by Grifols S.A.
  • 2. CSL Behring
  • 3. Kedrion Biopharma Inc.
  • 4. Octapharma AG
  • 5. Takeda Pharmaceutical Company Limited
  • 6. The Bio Products Laboratory

LIST OF FIGURES

  • FIGURE 1. SUBCUTANEOUS IMMUNOGLOBULIN MARKET RESEARCH PROCESS
  • FIGURE 2. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. SUBCUTANEOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SUBCUTANEOUS IMMUNOGLOBULIN MARKET DYNAMICS
  • TABLE 7. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. SUBCUTANEOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2023